Randomized trial evaluates pimavanserin’s effects on Parkinson’s disease psychosis, suggesting beneficial outcomes.
To evaluate the efficacy and safety of pimavanserin in Parkinson’s disease psychosis (PDP) through a meta-analysis of placebo-controlled randomized controlled trials (RCTs).
No takes yet. Share an insight, caveat, or question.
Petruncio et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: